Nick Paul Taylor

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive who played a role in the commercialization of Trodelvy and Opdivo.

More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.

Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous system. The call for more spending rang out from a survey, which found neurology patient groups are less satisfied with the current level of investment than their peers in other therapeutic areas.

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.

Sage Therapeutics' dalzanemdor has flamed out, recording its third midphase flop in seven months.

A phase 3 trial of NewAmsterdam Pharma's cholesterol-lowering candidate hit its co-primary endpoints, teeing the biotech up to file for approval.

The partnership will support data flows that enable people who use both companies’ devices to track how glucose levels affect other health metrics.

A facility in Lexington will close and employees at Cambridge and Plainville plants will be laid off starting in January.

A patient has died after receiving the high dose of Neurogene's Rett syndrome gene therapy candidate.

Fortimedix develops flexible surgical instruments that are responsive enough to navigate the body and enable endoscopic and minimally invasive procedures.